Norfolk, VA, June 1, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the...
Read MorePresenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company’s dual action complement inhibitor and innate anti-inflammatory product...
Read More